Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Xtant Medical Holdings Inc (XTNT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XTNT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.75
1 Year Target Price $1.75
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.65% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 90.60M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) 2 | Beta -0.22 | 52 Weeks Range 0.33 - 0.78 | Updated Date 08/15/2025 |
52 Weeks Range 0.33 - 0.78 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.01 | Actual 0.02 |
Profitability
Profit Margin -3.59% | Operating Margin (TTM) 13.06% |
Management Effectiveness
Return on Assets (TTM) 0.02% | Return on Equity (TTM) -9.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 120752858 | Price to Sales(TTM) 0.71 |
Enterprise Value 120752858 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 0.95 | Enterprise Value to EBITDA 26.37 | Shares Outstanding 139323008 | Shares Floating 25925010 |
Shares Outstanding 139323008 | Shares Floating 25925010 | ||
Percent Insiders 15.71 | Percent Institutions 56.12 |
Upturn AI SWOT
Xtant Medical Holdings Inc
Company Overview
History and Background
Xtant Medical Holdings Inc. (ticker symbol: XTNT) focuses on the development, commercialization, and marketing of regenerative medicine products and surgical implants. Founded in 2000, the company has evolved through various acquisitions and strategic shifts to focus on spinal and orthopedic solutions. It has navigated financial challenges and restructuring to refine its product offerings and market focus.
Core Business Areas
- Spinal Implants and Biologics: Develops, manufactures, and markets a comprehensive portfolio of spinal implants and biologics used in spinal fusion procedures. Focus is on providing solutions that promote bone growth and stability.
- Orthopedic Products: Offers a range of orthopedic products focused on trauma and extremity reconstruction. These include fixation devices and tissue-based products to aid in fracture repair and bone regeneration.
Leadership and Structure
The company's leadership team consists of the CEO, CFO, and other key executives responsible for strategic direction, operations, and financial management. Xtant Medical is structured into functional departments including sales, marketing, research and development, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- OsteoSync: A family of bone graft products that use proprietary technologies. Estimated revenue is not available, but they are important for spinal fusion. Competitors include Medtronic (MDT) and NuVasive (NUVA).
- 4Bone: A demineralized bone matrix (DBM) product used as a bone graft substitute. Estimated revenue is not publicly available, but it is an important product. Competitors include Stryker (SYK) and Zimmer Biomet (ZBH).
Market Dynamics
Industry Overview
The spinal and orthopedic implant market is driven by an aging population, increasing prevalence of spinal disorders, and advancements in surgical techniques and biomaterials. The market is competitive, with large players holding significant market share.
Positioning
Xtant Medical is positioned as a smaller player in the spinal and orthopedic market, focusing on innovation in regenerative medicine and biologics. They compete with larger, more established companies.
Total Addressable Market (TAM)
The global spinal implants and biologics market is estimated to be in the billions of dollars. Xtant Medical has a small percentage of the TAM and has opportunities to grow through product development and market expansion.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Focus on regenerative medicine
- Established distribution network
Weaknesses
- Limited financial resources
- Smaller market share compared to competitors
- History of net losses
Opportunities
- Expanding product offerings
- Strategic partnerships and acquisitions
- Growing demand for minimally invasive surgical procedures
Threats
- Intense competition
- Regulatory changes
- Pricing pressures from healthcare providers
Competitors and Market Share
Key Competitors
- MDT
- NUVA
- SYK
- ZBH
Competitive Landscape
Xtant Medical faces significant competition from larger companies with greater resources and established market positions. The company's competitive advantage lies in its innovative products and focus on regenerative medicine, but it must overcome financial challenges to achieve sustainable growth.
Major Acquisitions
Xtant Medical acquired RTI Surgical's spine business
- Year: 2020
- Acquisition Price (USD millions): 32
- Strategic Rationale: Expanded Xtant Medical's spinal implant portfolio and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of rapid expansion followed by periods of restructuring and financial challenges.
Future Projections: Future growth is dependent on the success of new product launches, strategic partnerships, and improved financial management. Analyst estimates vary, but generally project moderate revenue growth over the next few years.
Recent Initiatives: Recent initiatives include new product development, expansion of the sales force, and cost reduction measures.
Summary
Xtant Medical is a small player in a competitive market with an innovative portfolio but faces financial challenges. While its focus on regenerative medicine provides an edge, consistent profitability remains elusive. The company needs to carefully manage its resources and capitalize on market opportunities to achieve sustainable growth, especially amidst strong competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Materials
- Third-party Market Research Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xtant Medical Holdings Inc
Exchange NYSE MKT | Headquaters Belgrade, MT, United States | ||
IPO Launch date 2015-10-19 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 217 | Website https://xtantmedical.com |
Full time employees 217 | Website https://xtantmedical.com | ||
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.